Martin Allen-Auerbach

Title(s)HS Clinical Professor, Molecular and Medical Pharmacology
SchoolMedicine
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Larger Tumor Size and Elevated Serum Chromogranin A Levels Predict Metastatic Disease on DOTATATE Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors. Ann Surg Oncol. 2024 Jun 22. Labora A, Shimizu T, Moore A, Premji A, Armstrong WR, Chen KY, Link J, Chan CS, Allen-Auerbach MS, Donahue TR. PMID: 38909116.
      View in: PubMed   Mentions:    Fields:    
    2. FAPI PET uptake patterns after invasive medical interventions: a single center retrospective analysis. Eur J Nucl Med Mol Imaging. 2024 Sep; 51(11):3373-3385. Maliha PG, Hotta M, Farolfi A, Grogan T, Alano R, Limon A, Lam E, Carlucci G, Bahri S, Salavati A, Benz M, Silverman D, Gupta P, Quon A, Allen-Auerbach M, Czernin J, Calais J. PMID: 38750372.
      View in: PubMed   Mentions:    Fields:    
    3. PSMA PET/CT Dual-Time-Point Imaging: Nice to Have or Need to Have? J Nucl Med. 2024 May 01; 65(5):818-819. Unterrainer LM, Ruchalski K, Allen-Auerbach MS, Calais J, Benz MR. PMID: 38176724.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    4. Differences and Common Ground in 177Lu-PSMA Radioligand Therapy Practice Patterns: International Survey of 95 Theranostic Centers. J Nucl Med. 2024 Mar 01; 65(3):438-445. Farolfi A, Armstrong WR, Djaileb L, Gafita A, Hotta M, Allen-Auerbach M, Unterrainer LM, Fendler WP, Rettig M, Eiber M, Hofman MS, Hadaschik B, Herrmann K, Czernin J, Calais J, Benz MR. PMID: 38238041.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    5. Malignant Pheochromocytoma Presenting as a Large Adrenal Mass With Cavoatrial Tumor Thrombus. AACE Clin Case Rep. 2024 May-Jun; 10(3):117-118. Yu R, Allen-Auerbach MS, Yeh MW. PMID: 38799044; PMCID: PMC11127590.
      View in: PubMed   Mentions:
    6. Visual and whole-body quantitative analyses of 68 Ga-DOTATATE PET/CT for prognosis of outcome after PRRT with 177Lu-DOTATATE. Ann Nucl Med. 2024 Apr; 38(4):296-304. Hotta M, Sonni I, Thin P, Nguyen K, Gardner L, Ciuca L, Hayrapetian A, Lewis M, Lubin D, Allen-Auerbach M. PMID: 38252228.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    7. Do Bone Scans Overstage Disease Compared with PSMA PET at Initial Staging? An International Multicenter Retrospective Study with Masked Independent Readers. J Nucl Med. 2023 11; 64(11):1744-1747. Hope TA, Benz M, Jiang F, Thompson D, Barbato F, Juarez R, Hernandez Pampaloni M, Allen-Auerbach M, Gupta P, Fendler WP, Calais J. PMID: 37591547.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    8. 68Ga-FAPI-46 PET/CT Tracer Uptake in CT-diagnosed Intra-Abdominal Fat Necrosis. Radiol Imaging Cancer. 2023 07; 5(4):e230026. Maliha PG, Allen-Auerbach M, Hotta M, Calais J. PMID: 37389447; PMCID: PMC10413291.
      View in: PubMed   Mentions:    Fields:    
    9. PSMA-Negative Lesion Progression Under 177Lu-PSMA Radioligand Therapy. J Nucl Med. 2023 09; 64(9):1502-1503. Murthy V, Allen-Auerbach M, Lam R, Owen D, Czernin J, Calais J. PMID: 37321828.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    10. 68Ga-FAPI PET/CT Interobserver Agreement on Tumor Assessment: An International Multicenter Prospective Study. J Nucl Med. 2023 07; 64(7):1043-1048. Mei R, Kessler L, Pabst KM, Weber M, Schmidkonz C, Rischpler C, Zacho HD, Hope T, Schwarzenböck SM, Allen-Auerbach M, Emmett L, Ferdinandus J, Unterrainer M, Schaarschmidt BM, Umutlu L, Farolfi A, Castellucci P, Nanni C, Telo S, Fanti S, Herrmann K, Fendler WP. PMID: 37230530.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    11. CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma. Cancer Discov. 2023 03 01; 13(3):580-597. Larson SM, Walthers CM, Ji B, Ghafouri SN, Naparstek J, Trent J, Chen JM, Roshandell M, Harris C, Khericha M, Schweppe T, Berent-Maoz B, Gosliner SB, Almaktari A, Ceja MA, Allen-Auerbach MS, Said J, Nawaly K, Mead M, de Vos S, Young PA, Oliai C, Schiller GJ, Timmerman JM, Ribas A, Chen YY. PMID: 36416874; PMCID: PMC9992104.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    12. SNMMI Procedure Standard/EANM Practice Guideline for SSTR PET: Imaging Neuroendocrine Tumors. J Nucl Med. 2023 02; 64(2):204-210. Hope TA, Allen-Auerbach M, Bodei L, Calais J, Dahlbom M, Dunnwald LK, Graham MM, Jacene HA, Heath CL, Mittra ES, Wright CL, Fendler WP, Herrmann K, Taïeb D, Kjaer A. PMID: 36725249.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    13. Pretreatment visceral metastases in castration resistant metastatic prostate cancer: role in prediction versus actual site of disease progression. Cancer Imaging. 2022 Jul 14; 22(1):34. Ruchalski K, Kim HJ, Douek M, Raman S, Patel M, Sai V, Gutierrez A, Levine B, Fischer C, Allen-Auerbach M, Gupta P, Coy H, Villegas B, Brown M, Goldin J. PMID: 35836271; PMCID: PMC9281063.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    14. Discovery and characterization of circulating tumor cell clusters in neuroendocrine tumor patients using nanosubstrate-embedded microchips. Biosens Bioelectron. 2022 Mar 01; 199:113854. Sun N, Yang Y, Miao H, Redublo P, Liu H, Liu W, Huang YW, Teng PC, Zhang C, Zhang RY, Smalley M, Yang P, Chou SJ, Huai K, Zhang Z, Lee YT, Wang JJ, Wang J, Liang IY, Zhang TX, Zhang D, Liang L, Weiss PS, Posadas EM, Donahue T, Hecht JR, Allen-Auerbach MS, Bergsland EK, Hope TA, Pei R, Zhu Y, Tseng HR, Heaney AP. PMID: 34896918; PMCID: PMC8900541.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    15. Head-to-Head Comparison of 68Ga-PSMA-11 PET/CT and mpMRI with a Histopathology Gold Standard in the Detection, Intraprostatic Localization, and Determination of Local Extension of Primary Prostate Cancer: Results from a Prospective Single-Center Imaging Trial. J Nucl Med. 2022 06; 63(6):847-854. Sonni I, Felker ER, Lenis AT, Sisk AE, Bahri S, Allen-Auerbach M, Armstrong WR, Suvannarerg V, Tubtawee T, Grogan T, Elashoff D, Eiber M, Raman SS, Czernin J, Reiter RE, Calais J. PMID: 34649942; PMCID: PMC9157724.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCTClinical Trials
    16. High 68 Ga-FAPI-46 uptake in a pulmonary necrotizing granuloma in a patient with subcutaneous lipoma. Eur J Nucl Med Mol Imaging. 2022 02; 49(3):1088-1089. Hotta M, Benz MR, Allen-Auerbach MS, Crompton JG, Roth MD, Eilber FC, Calais J. PMID: 34546387.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    17. Safety of PSMA-Targeted Molecular Radioligand Therapy with 177Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312). J Nucl Med. 2021 Oct; 62(10):1447-1456. Calais J, Czernin J, Thin P, Gartmann J, Nguyen K, Armstrong WR, Allen-Auerbach M, Quon A, Bahri S, Gupta P, Gardner L, Dahlbom M, He B, Esfandiari R, Ranganathan D, Herrmann K, Eiber M, Fendler WP, Delpassand E. PMID: 34272322; PMCID: PMC8724902.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    18. Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort. J Nucl Med. 2021 Oct; 62(10):1440-1446. Calais J, Gafita A, Eiber M, Armstrong WR, Gartmann J, Thin P, Nguyen K, Lok V, Gosa L, Grogan T, Esfandiari R, Allen-Auerbach M, Quon A, Bahri S, Gupta P, Gardner L, Ranganathan D, Slavik R, Dahlbom M, Herrmann K, Delpassand E, Fendler WP, Czernin J. PMID: 34016732; PMCID: PMC8724893.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    19. The Impact of Monosodium Glutamate on 68Ga-PSMA-11 Biodistribution in Men with Prostate Cancer: A Prospective Randomized, Controlled Imaging Study. J Nucl Med. 2021 Sep 01; 62(9):1244-1251. Armstrong WR, Gafita A, Zhu S, Thin P, Nguyen K, Alano R, Lira S, Booker K, Gardner L, Grogan T, Elashoff D, Allen-Auerbach M, Dahlbom M, Czernin J, Calais J. PMID: 33509974; PMCID: PMC9364769.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    20. [18F]FDG PET/CT for evaluating early response to neoadjuvant chemotherapy in pediatric patients with sarcoma: a prospective single-center trial. EJNMMI Res. 2020 Oct 15; 10(1):122. Polverari G, Ceci F, Passera R, Crane J, Du L, Li G, Fanti S, Bernthal N, Eilber FC, Allen-Auerbach M, Czernin J, Calais J, Federman N. PMID: 33063147; PMCID: PMC7561652.
      View in: PubMed   Mentions: 1  
    21. Unacceptable Denials. J Nucl Med. 2020 07; 61(7):939. Czernin J, Allen-Auerbach M. PMID: 32611710.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    22. Editor's Page: Unacceptable Denials. J Nucl Med. 2020 May 01. Czernin J, Allen-Auerbach M. PMID: 32358085.
      View in: PubMed   Mentions:    Fields:    
    23. Transforming an Academic Radiochemistry Facility for Positron Emission Tomography Drug cGMP Compliance. Mol Imaging Biol. 2020 04; 22(2):256-264. Zhu S, Mosessian S, Kroeger K, Sadeghi S, Slavik R, Kinloch S, Moore M, Allen-Auerbach M, Czernin J, Phelps M. PMID: 31240531.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    24. Nuclear Medicine Operations in the Times of COVID-19: Strategies, Precautions, and Experiences. J Nucl Med. 2020 05; 61(5):626-629. Czernin J, Fanti S, Meyer PT, Allen-Auerbach M, Hacker M, Sathekge M, Hicks R, Scott AM, Hatazawa J, Yun M, Schöder H, Bartenstein P, Herrmann K. PMID: 32238430.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCellsPHPublic Health
    25. Of Sheep and Wolves: Curtailing Coverage for Essential Imaging Tests Based on Flawed Use and Cost Arguments. J Nucl Med. 2019 12; 60(12):1657-1658. Czernin J, Allen-Auerbach M, Calais J. PMID: 31792126.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    26. Solitary Mucinous Prostate Adenocarcinoma Lung Metastasis Detected by 68Ga-PSMA-11 PET/CT. Clin Genitourin Cancer. 2019 02; 17(1):e53-e55. Polverari G, Ceci F, Allen-Auerbach M, Gupta P, Fishbein MC, Reiter RE, Lee JM, Hope TA, Carroll RM, Czernin J, Calais J. PMID: 30293922.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    27. Quantitative bone scan lesion area as an early surrogate outcome measure indicative of overall survival in metastatic prostate cancer. J Med Imaging (Bellingham). 2018 Jan; 5(1):011017. Brown MS, Kim GHJ, Chu GH, Ramakrishna B, Allen-Auerbach M, Fischer CP, Levine B, Gupta PK, Schiepers CW, Goldin JG. PMID: 29340285; PMCID: PMC5764115.
      View in: PubMed   Mentions: 5  
    28. Impact of 68Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence. J Nucl Med. 2018 03; 59(3):434-441. Calais J, Fendler WP, Eiber M, Gartmann J, Chu FI, Nickols NG, Reiter RE, Rettig MB, Marks LS, Ahlering TE, Huynh LM, Slavik R, Gupta P, Quon A, Allen-Auerbach MS, Czernin J, Herrmann K. PMID: 29242398; PMCID: PMC5868499.
      View in: PubMed   Mentions: 63     Fields:    Translation:Humans
    29. Most of the Intended Management Changes After 68Ga-DOTATATE PET/CT Are Implemented. J Nucl Med. 2017 11; 58(11):1793-1796. Calais J, Czernin J, Eiber M, Fendler WP, Gartmann J, Heaney AP, Hendifar AE, Pisegna JR, Hecht JR, Wolin EM, Slavik R, Gupta P, Quon A, Schiepers C, Allen-Auerbach MS, Herrmann K. PMID: 28473600; PMCID: PMC5666645.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    30. 68Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study. J Nucl Med. 2017 10; 58(10):1617-1623. Fendler WP, Calais J, Allen-Auerbach M, Bluemel C, Eberhardt N, Emmett L, Gupta P, Hartenbach M, Hope TA, Okamoto S, Pfob CH, Pöppel TD, Rischpler C, Schwarzenböck S, Stebner V, Unterrainer M, Zacho HD, Maurer T, Gratzke C, Crispin A, Czernin J, Herrmann K, Eiber M. PMID: 28408531.
      View in: PubMed   Mentions: 62     Fields:    Translation:HumansCTClinical Trials
    31. Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma. Sci Transl Med. 2017 01 18; 9(373). Keu KV, Witney TH, Yaghoubi S, Rosenberg J, Kurien A, Magnusson R, Williams J, Habte F, Wagner JR, Forman S, Brown C, Allen-Auerbach M, Czernin J, Tang W, Jensen MC, Badie B, Gambhir SS. PMID: 28100832; PMCID: PMC5260938.
      View in: PubMed   Mentions: 156     Fields:    Translation:HumansCellsCTClinical Trials
    32. The incidence of thyroid cancer in focal hypermetabolic thyroid lesions: an 18F-FDG PET/CT study in more than 6000 patients. Nucl Med Commun. 2016 Dec; 37(12):1290-1296. Barrio M, Czernin J, Yeh MW, Palma Diaz MF, Gupta P, Allen-Auerbach M, Schiepers C, Herrmann K. PMID: 27612034; PMCID: PMC5077695.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    33. Human Biodistribution and Radiation Dosimetry of 18F-Clofarabine, a PET Probe Targeting the Deoxyribonucleoside Salvage Pathway. J Nucl Med. 2017 03; 58(3):374-378. Barrio MJ, Spick C, Radu CG, Lassmann M, Eberlein U, Allen-Auerbach M, Schiepers C, Slavik R, Czernin J, Herrmann K. PMID: 27811125; PMCID: PMC6945110.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    34. 68Ga-DOTATATE PET/CT Interobserver Agreement for Neuroendocrine Tumor Assessment: Results of a Prospective Study on 50 Patients. J Nucl Med. 2017 02; 58(2):307-311. Fendler WP, Barrio M, Spick C, Allen-Auerbach M, Ambrosini V, Benz M, Bluemel C, Grewal RK, Lapa C, Miederer M, Nicolas G, Schuster T, Czernin J, Herrmann K. PMID: 27539839; PMCID: PMC5290122.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    35. SPECT- and PET-based patient-tailored treatment in neuroendocrine tumors: a comprehensive multidisciplinary team approach. Clin Nucl Med. 2015 May; 40(5):e271-7. Werner RA, Bluemel C, Lassmann M, Kudlich T, Higuchi T, Lopci E, Allen-Auerbach M, Colletti PM, Rubello D, Zatelli MC, Herrmann K. PMID: 25642915.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    36. Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy. EJNMMI Res. 2014; 4:74. Lapa C, Werner RA, Bluemel C, Lueckerath K, Muegge DO, Strate A, Haenscheid H, Schirbel A, Allen-Auerbach MS, Bundschuh RA, Buck AK, Herrmann K. PMID: 25977880; PMCID: PMC4412196.
      View in: PubMed   Mentions: 7  
    37. Impact of 68Ga-DOTATATE PET/CT on the management of neuroendocrine tumors: the referring physician's perspective. J Nucl Med. 2015 Jan; 56(1):70-5. Herrmann K, Czernin J, Wolin EM, Gupta P, Barrio M, Gutierrez A, Schiepers C, Mosessian S, Phelps ME, Allen-Auerbach MS. PMID: 25500825; PMCID: PMC5068919.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    38. Perceived misinterpretation rates in oncologic 18F-FDG PET/CT studies: a survey of referring physicians. J Nucl Med. 2014 Dec; 55(12):1925-9. Karantanis D, Kalkanis D, Czernin J, Herrmann K, Pomykala KL, Bogsrud TV, Subramaniam RM, Lowe VJ, Allen-Auerbach MS. PMID: 25453041; PMCID: PMC4324619.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    39. 68Gallium- and 90Yttrium-/ 177Lutetium: "theranostic twins" for diagnosis and treatment of NETs. Ann Nucl Med. 2015 Jan; 29(1):1-7. Werner RA, Bluemel C, Allen-Auerbach MS, Higuchi T, Herrmann K. PMID: 25139472; PMCID: PMC4306729.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    40. Clinical use of bone-targeting radiopharmaceuticals with focus on alpha-emitters. World J Radiol. 2014 Jul 28; 6(7):480-5. Wieder HA, Lassmann M, Allen-Auerbach MS, Czernin J, Herrmann K. PMID: 25071888; PMCID: PMC4109099.
      View in: PubMed   Mentions: 4  
    41. Oncologic PET/CT interpretation and reporting approaches. Survey in clinical practice. Nuklearmedizin. 2014; 53(2):19-25. Karantanis D, Kalkanis D, Allen-Auerbach MS, Herrmann K, Pomykala KL, Bogsrud TV, Lowe VJ, Czernin J. PMID: 24473996.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    42. (18)F-FDOPA PET for differentiating recurrent or progressive brain metastatic tumors from late or delayed radiation injury after radiation treatment. J Nucl Med. 2014 Jan; 55(1):30-6. Lizarraga KJ, Allen-Auerbach M, Czernin J, DeSalles AA, Yong WH, Phelps ME, Chen W. PMID: 24167081.
      View in: PubMed   Mentions: 51     Fields:    Translation:HumansPHPublic Health
    43. PET/computed tomography and lymphoma. Radiol Clin North Am. 2013 Sep; 51(5):833-44. Allen-Auerbach M, de Vos S, Czernin J. PMID: 24010908.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    44. PET/CT in Oncology: Current Status and Perspectives. Curr Radiol Rep. 2013; 1:177-190. Czernin J, Allen-Auerbach M, Nathanson D, Herrmann K. PMID: 24883234; PMCID: PMC4034170.
      View in: PubMed   Mentions: 33  
    45. Oncologic 18F-FDG PET/CT: referring physicians' point of view. J Nucl Med. 2012 Oct; 53(10):1499-505. Karantanis D, Kalkanis D, Allen-Auerbach M, Bogsrud TV, Subramaniam RM, Danielson A, Lowe VJ, Czernin J. PMID: 22917886.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    46. Squamous papilloma of the oral cavity and oropharynx on 18F-FDG PET/CT imaging. Clin Nucl Med. 2012 May; 37(5):e98-9. Karantanis D, Allen-Auerbach M, Czernin J. PMID: 22475925.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    47. Computer-aided quantitative bone scan assessment of prostate cancer treatment response. Nucl Med Commun. 2012 Apr; 33(4):384-94. Brown MS, Chu GH, Kim HJ, Allen-Auerbach M, Poon C, Bridges J, Vidovic A, Ramakrishna B, Ho J, Morris MJ, Larson SM, Scher HI, Goldin JG. PMID: 22367858; PMCID: PMC3294499.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    48. Is there a need for dedicated bone imaging in addition to 18F-FDG PET/CT imaging in pediatric sarcoma patients? J Pediatr Hematol Oncol. 2012 Mar; 34(2):131-6. Walter F, Czernin J, Hall T, Allen-Auerbach M, Walter MA, Dunkelmann S, Federman N. PMID: 22134608.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    49. 18F-FDG-PET/CT Imaging as an early survival predictor in patients with primary high-grade soft tissue sarcomas undergoing neoadjuvant therapy. Clin Cancer Res. 2012 Apr 01; 18(7):2024-31. Herrmann K, Benz MR, Czernin J, Allen-Auerbach MS, Tap WD, Dry SM, Schuster T, Eckardt JJ, Phelps ME, Weber WA, Eilber FC. PMID: 22338012; PMCID: PMC3431618.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    50. Relationship among glycolytic phenotype, grade, and histological subtype in ovarian carcinoma. Clin Nucl Med. 2012 Jan; 37(1):49-53. Karantanis D, Allen-Auerbach M, Czernin J. PMID: 22157028.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    51. Sources and resources for oncologists to help answer the question: is PET/CT appropriate for my patient? Hell J Nucl Med. 2012 Jan-Apr; 15(1):2-8. Karantanis D, Allen-Auerbach M, Czernin J. PMID: 22413105.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    52. (18)F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib. J Nucl Med. 2011 Nov; 52(11):1684-1689. Benz MR, Herrmann K, Walter F, Garon EB, Reckamp KL, Figlin R, Phelps ME, Weber WA, Czernin J, Allen-Auerbach MS. PMID: 22045706; PMCID: PMC5021512.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCTClinical Trials
    53. 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography for response assessment in soft tissue sarcoma: a pilot study to correlate imaging findings with tissue thymidine kinase 1 and Ki-67 activity and histopathologic response. Cancer. 2012 Jun 15; 118(12):3135-44. Benz MR, Czernin J, Allen-Auerbach MS, Dry SM, Sutthiruangwong P, Spick C, Radu C, Weber WA, Tap WD, Eilber FC. PMID: 22020872; PMCID: PMC3436595.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    54. 18F-fluorodeoxyglucose uptake of bone and soft tissue sarcomas in pediatric patients. Pediatr Hematol Oncol. 2011 Oct; 28(7):579-87. Walter F, Federman N, Apichairuk W, Nelson S, Phelps ME, Allen-Auerbach M, Walter MA, Czernin J. PMID: 21936620.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    55. Breast cancer. Methods Mol Biol. 2011; 727:141-70. Czernin J, Benz MR, Allen-Auerbach MS. PMID: 21331933.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    56. Correlation between glycolytic phenotype and tumor grade in soft-tissue sarcomas by 18F-FDG PET. J Nucl Med. 2010 Aug; 51(8):1174-81. Benz MR, Dry SM, Eilber FC, Allen-Auerbach MS, Tap WD, Elashoff D, Phelps ME, Czernin J. PMID: 20660389; PMCID: PMC3197812.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
    57. FDG-PET/CT Imaging Predicts Histopathologic Treatment Responses after Neoadjuvant Therapy in Adult Primary Bone Sarcomas. Sarcoma. 2010; 2010:143540. Benz MR, Czernin J, Tap WD, Eckardt JJ, Seeger LL, Allen-Auerbach MS, Dry SM, Phelps ME, Weber WA, Eilber FC. PMID: 20414348; PMCID: PMC2855986.
      View in: PubMed   Mentions: 13  
    58. Imaging of CTLA4 blockade-induced cell replication with (18)F-FLT PET in patients with advanced melanoma treated with tremelimumab. J Nucl Med. 2010 Mar; 51(3):340-6. Ribas A, Benz MR, Allen-Auerbach MS, Radu C, Chmielowski B, Seja E, Williams JL, Gomez-Navarro J, McCarthy T, Czernin J. PMID: 20150263.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansCTClinical Trials
    59. PET/CT imaging: The incremental value of assessing the glucose metabolic phenotype and the structure of cancers in a single examination. Eur J Radiol. 2010 Mar; 73(3):470-80. Czernin J, Benz MR, Allen-Auerbach MS. PMID: 20097498.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    60. Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign. Cancer. 2010 Jan 15; 116(2):451-8. Benz MR, Czernin J, Dry SM, Tap WD, Allen-Auerbach MS, Elashoff D, Phelps ME, Weber WA, Eilber FC. PMID: 19924789; PMCID: PMC3188986.
      View in: PubMed   Mentions: 62     Fields:    Translation:HumansCTClinical Trials
    61. Measuring response with FDG-PET: methodological aspects. Oncologist. 2009 Apr; 14(4):369-77. Allen-Auerbach M, Weber WA. PMID: 19357228.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    62. FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas. Clin Cancer Res. 2009 Apr 15; 15(8):2856-63. Benz MR, Czernin J, Allen-Auerbach MS, Tap WD, Dry SM, Elashoff D, Chow K, Evilevitch V, Eckardt JJ, Phelps ME, Weber WA, Eilber FC. PMID: 19351756; PMCID: PMC4068269.
      View in: PubMed   Mentions: 61     Fields:    Translation:Humans
    63. PET Imaging of Prostate Cancer Using C-Acetate. PET Clin. 2009 Apr; 4(2):163-72. Czernin J, Benz MR, Allen-Auerbach MS. PMID: 21984877; PMCID: PMC3188983.
      View in: PubMed   Mentions: 19     Fields:    
    64. Comparison of CT, PET, and PET/CT for staging of patients with indolent non-Hodgkin's lymphoma. Mol Imaging Biol. 2009 Jul-Aug; 11(4):269-74. Fueger BJ, Yeom K, Czernin J, Sayre JW, Phelps ME, Allen-Auerbach MS. PMID: 19326177; PMCID: PMC2693779.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    65. Death from metastatic donor-derived ovarian cancer in a male kidney transplant recipient. Am J Transplant. 2009 Feb; 9(2):428-32. Lipshutz GS, Mihara N, Wong R, Wallace WD, Allen-Auerbach M, Dorigo O, Rao PN, Pham PC, Pham PT. PMID: 19178417.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    66. Combined assessment of metabolic and volumetric changes for assessment of tumor response in patients with soft-tissue sarcomas. J Nucl Med. 2008 Oct; 49(10):1579-84. Benz MR, Allen-Auerbach MS, Eilber FC, Chen HJ, Dry S, Phelps ME, Czernin J, Weber WA. PMID: 18794268; PMCID: PMC4068272.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCells
    67. Treatment monitoring by 18F-FDG PET/CT in patients with sarcomas: interobserver variability of quantitative parameters in treatment-induced changes in histopathologically responding and nonresponding tumors. J Nucl Med. 2008 Jul; 49(7):1038-46. Benz MR, Evilevitch V, Allen-Auerbach MS, Eilber FC, Phelps ME, Czernin J, Weber WA. PMID: 18552153; PMCID: PMC4070847.
      View in: PubMed   Mentions: 42     Fields:    Translation:Humans
    68. The impact of fluorodeoxyglucose-positron emission tomography in primary staging and patient management in lymphoma patients. Radiol Clin North Am. 2008 Mar; 46(2):199-211, vii. Allen-Auerbach M, de Vos S, Czernin J. PMID: 18619376.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    69. Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas. Clin Cancer Res. 2008 Feb 01; 14(3):715-20. Evilevitch V, Weber WA, Tap WD, Allen-Auerbach M, Chow K, Nelson SD, Eilber FR, Eckardt JJ, Elashoff RM, Phelps ME, Czernin J, Eilber FC. PMID: 18245531.
      View in: PubMed   Mentions: 52     Fields:    Translation:Humans
    70. Pancreas volumes in humans from birth to age one hundred taking into account sex, obesity, and presence of type-2 diabetes. Clin Anat. 2007 Nov; 20(8):933-42. Saisho Y, Butler AE, Meier JJ, Monchamp T, Allen-Auerbach M, Rizza RA, Butler PC. PMID: 17879305; PMCID: PMC2680737.
      View in: PubMed   Mentions: 194     Fields:    Translation:Humans
    71. Accuracy of PET/CT in characterization of solitary pulmonary lesions. J Nucl Med. 2007 Feb; 48(2):214-20. Kim SK, Allen-Auerbach M, Goldin J, Fueger BJ, Dahlbom M, Brown M, Czernin J, Schiepers C. PMID: 17268017.
      View in: PubMed   Mentions: 88     Fields:    Translation:Humans
    72. Evaluation of suspected local recurrence in head and neck cancer: a comparison between PET and PET/CT for biopsy proven lesions. Eur J Radiol. 2007 May; 62(2):199-204. Halpern BS, Yeom K, Fueger BJ, Lufkin RB, Czernin J, Allen-Auerbach M. PMID: 17223003.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    73. Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006. J Nucl Med. 2007 Jan; 48 Suppl 1:78S-88S. Czernin J, Allen-Auerbach M, Schelbert HR. PMID: 17204723.
      View in: PubMed   Mentions: 123     Fields:    
    74. Standard PET/CT of the chest during shallow breathing is inadequate for comprehensive staging of lung cancer. J Nucl Med. 2006 Feb; 47(2):298-301. Allen-Auerbach M, Yeom K, Park J, Phelps M, Czernin J. PMID: 16455636.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    75. Performance of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography and integrated PET/CT in restaged breast cancer patients. Mol Imaging Biol. 2005 Sep-Oct; 7(5):369-76. Fueger BJ, Weber WA, Quon A, Crawford TL, Allen-Auerbach MS, Halpern BS, Ratib O, Phelps ME, Czernin J. PMID: 16220355.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    76. Comparison between 18F-FDG PET, in-line PET/CT, and software fusion for restaging of recurrent colorectal cancer. J Nucl Med. 2005 Apr; 46(4):587-95. Kim JH, Czernin J, Allen-Auerbach MS, Halpern BS, Fueger BJ, Hecht JR, Ratib O, Phelps ME, Weber WA. PMID: 15809480.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    77. Comparison between 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma. Mol Imaging Biol. 2004 Nov-Dec; 6(6):411-6. Allen-Auerbach M, Quon A, Weber WA, Obrzut S, Crawford T, Silverman DH, Ratib O, Phelps ME, Czernin J. PMID: 15564152.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    78. Relationship between coronary function by positron emission tomography and temporal changes in morphology by intravascular ultrasound (IVUS) in transplant recipients. J Heart Lung Transplant. 1999 Mar; 18(3):211-9. Allen-Auerbach M, Schöder H, Johnson J, Kofoed K, Einhorn K, Phelps ME, Kobashigawa J, Czernin J. PMID: 10328146.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    Martin's Networks
    Concepts (264)
    Derived automatically from this person's publications.
    _
    Co-Authors (69)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _